Roth Capital Initiates Coverage On Prosensa At Neutral; Sets $12 Price Target
In a research note released this morning, Roth Capital analyst Debjit Chattopadhyay initiated coverage with a “Neutral” rating on Prosensa Holding N.V. (RNA) and a price target of $12.00 a share.
“Prosensa is a leader in RNA-based therapeutics and has the most advanced pipeline in Duchenne Muscular Dystrophy, in our opinion. The recent accommodating regulatory environment has driven the stock up ~150%, but we see challenges for drisapersen and believe the expectations are high. In our opinion, the available clinical evidence may not support an accelerated approval in the U.S. and initiate with a Neutral rating”, Chattopadhyay wrote.